These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1588370)

  • 1. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.
    Nordic Gastrointestinal Tumor Adjuvant Therapy Group
    J Clin Oncol; 1992 Jun; 10(6):904-11. PubMed ID: 1588370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial.
    Nordic Gastrointestinal Tumor Adjuvant Therapy Group
    J Clin Oncol; 1989 Oct; 7(10):1437-46. PubMed ID: 2674332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
    Abad A; Garcia P; Gravalos C; Tusquets I; Font A; Perez G; Cortés-Funes H; Fabregat X; Barnadas A; Rosell R
    Cancer; 1995 Mar; 75(6):1238-44. PubMed ID: 7882275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group.
    Glimelius B
    Ann Oncol; 1993 Mar; 4(3):235-40. PubMed ID: 8471555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postsurgical sequential methotrexate/5-FU and leucovorin on outpatient basis for advanced colorectal carcinoma.
    Tokunaga Y; Kitaoka A; Yagi T; Tokuka A; Ohsumi K
    Hepatogastroenterology; 2001; 48(37):128-32. PubMed ID: 11268947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin.
    Pronzato P; Vaira F; Vigani A; Losardo P; Bertelli G
    Anticancer Res; 1995; 15(6B):2679-82. PubMed ID: 8669846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer.
    Jones DV; Winn RJ; Brown BW; Levy LB; Pugh RP; Wade JL; Gross HM; Pendergrass KB; Levin B; Abbruzzese JL
    Cancer; 1995 Nov; 76(10):1709-14. PubMed ID: 8625038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study.
    Glimelius B; Graf W; Hoffman K; Påhlman L; Sjödén PO; Wennberg A
    Acta Oncol; 1992; 31(6):645-51. PubMed ID: 1281650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
    Valone FH; Friedman MA; Wittlinger PS; Drakes T; Eisenberg PD; Malec M; Hannigan JF; Brown BW
    J Clin Oncol; 1989 Oct; 7(10):1427-36. PubMed ID: 2789272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
    J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
    Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential methotrexate--5-FU--leucovorin (MFL) in advanced colorectal cancer.
    Glimelius B; Ginman C; Graffman S; Påhlman L; Ståhle E
    Eur J Cancer Clin Oncol; 1986 Mar; 22(3):295-300. PubMed ID: 3486768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens.
    Glimelius B; Hoffman K; Olafsdottir M; Påhlman L; Sjödén PO; Wennberg A
    Eur J Cancer Clin Oncol; 1989 May; 25(5):829-35. PubMed ID: 2472275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
    Machiavelli M; Leone BA; Romero A; Rabinovich MG; Vallejo CT; Bianco A; Pérez JE; Rodríguez R; Cuevas MA; Alvarez LA
    Am J Clin Oncol; 1991 Jun; 14(3):211-7. PubMed ID: 2031508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
    Blijham G; Wagener T; Wils J; de Greve J; Buset M; Bleiberg H; Lacave A; Dalmark M; Selleslag J; Collette L; Sahmoud T
    J Clin Oncol; 1996 Aug; 14(8):2266-73. PubMed ID: 8708716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
    J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer.
    Marsh JC; Bertino JR; Katz KH; Davis CA; Durivage HJ; Rome LS; Richards F; Capizzi RL; Farber LR; Pasquale DN
    J Clin Oncol; 1991 Mar; 9(3):371-80. PubMed ID: 1999706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
    Goldberg RM; Hatfield AK; Kahn M; Sargent DJ; Knost JA; O'Connell MJ; Krook JE; Maillard JA; Wiesenfeld M; Schaefer PL; Tirona MT; Moertel CG
    J Clin Oncol; 1997 Nov; 15(11):3320-9. PubMed ID: 9363861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
    Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
    J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.